▲ +109.85% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Constellation Pharmaceuticals in the last 3 months. The average price target is $45.29, with a high forecast of $75.00 and a low forecast of $20.00. The average price target represents a 109.85% upside from the last price of $21.58.
The current consensus among 7 polled investment analysts is to buy stock in Constellation Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.